[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"poly-cystic-ovary-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:poly-cystic-ovary-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,74,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100647121","phase-1-endeavor-an-exemestane-needed-dose-efficacy-and-verification-as-an-ovulation-induction-regimen-study-100647121",false,"NCT07706374","E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study","ENDEAVOR","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Premenopausal female (ages 18-40);\n* Undergone an evaluation for infertility at UNC Fertility;\n* Previously diagnosed with polycystic ovary syndrome\u002F polyendocrine metabolic ovarian syndrome (PCOS\u002FPMOS) via established clinical diagnostic criteria with no other identifiable cause of infertility (example- endometriosis, uterine fibroids), and recommended to begin ovulation induction therapy;\n* Have patent fallopian tubes on hysterosalpingogram;\n* Male partners must have a normal semen analysis if presenting with a male partner;\n* Individuals must be ovulation induction naïve (no history of use of ovulation induction medications);\n* Individuals must be able to read, speak, and understand English or Spanish sufficiently to provide informed consent and participate in study procedures.\n\nExclusion Criteria:\n\nAny individual who meets one or more of the following criteria will be excluded from participation:\n\n* Under 18 or over 40 years of age; Individuals without the diagnosis of PCOS;\n* Body mass index \\>40 kg\u002Fm\\^2; Abnormal hysterosalpingogram;\n* Abnormal semen analysis if presenting with a male partner;\n* History of ovulation induction medication use;\n* Allergy to exemestane;\n* Individuals with abnormalities of Pap smear or breast examination;\n* Pregnant females;\n* Individuals with moderate to severe renal impairment;\n* Individuals with moderate to severe hepatic impairment;\n* Currently taking any of the following medications due to known or potential interactions with exemestane: Cytochrome P-450 3A4 (CYP3A4), Everolimus (Afinitor), Apixaban (Eliquis), Rivaroxaban (Xarelto), Aspirin, Diphenhydramine (Benadryl), Rosuvastatin (Crestor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Atorvastatin (Lipitor), Pregabalin (Lyrica), Metoprolol, Semaglutide (Ozempic), Levothyroxine (Synthroid), Ondansetron (Zofran), Goserelin (Zoladex);\n* Individuals who require a Legally Authorized Representative (LAR) to provide consent on their behalf;\n* Difficulty or inability to swallow solid dosage forms (tablets\u002Fcapsules of study drug)","FEMALE","18 Years","40 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to learn if study drug exemestane will increase chances of ovulation for patients with polyendocrine metabolic ovarian syndrome (PMOS, formerly called polycystic ovary syndrome (PCOS)). It will also learn about side effects of study drug exemestane in this study population. The main questions it aims to answer are:\n\nDoes exemestane lead to ovulation for patients with polyendocrine metabolic ovarian syndrome (PMOS- formerly called PCOS)?\n\nResearchers will compare exemestane to a placebo (a look-alike substance that contains no drug) to see if exemestane helps PMOS patients ovulate.\n\nParticipants will:\n\nTake exemestane or a placebo every day for 5-10 days Visit the clinic three times for ultrasounds, labs, and to answer questions about side effects.\n\nIf they become pregnant during this study, they will tell us how their pregnancy went after the study via a registry online.",[27],"Poly Cystic Ovary Syndrome",[29,30,31],"ovulation","androgen","aromatase","RECRUITING","2026-08-11",{"date":35,"type":36},"2026-08-14","ACTUAL",{"date":38,"type":21},"2026-08",{"date":40,"type":21},"2030-01",{"name":42,"class":43},"University of North Carolina, Chapel Hill","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100641400","physical-activity-and-cardiometabolic-health-in-women-with-or-without-polycystic-ovary-syndrome-scopap-100641400","NCT07659392","Physical Activity and Cardiometabolic Health in Women With or Without Polycystic Ovary Syndrome (SCOPAP)","Cardiometabolic Health in Women With Overweight or Obesity, With or Without Polycystic Ovary Syndrome: Effects of a Targeted Adapted Physical Activity Program","SCOPAP","Inclusion Criteria:\n\n* Women aged 18 to 40 years (inclusive boundaries)\n* Women with a body mass index (BMI) between 25 and 40 kg\u002Fm²\n* Women performing no more than 150 minutes of moderate-to-vigorous physical activity per week\n* Women able to provide informed consent to participate\n* Women affiliated with a social security system\n* One group will consist of women with polycystic ovary syndrome, and another group will consist of women without polycystic ovary syndrome\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding, as declared by the participant\n* Postmenopausal women\n* Women currently receiving pharmacological treatment for obesity or who have received such treatment within the past two years\n* Women under legal protection measures (guardianship, curatorship, or judicial protection)\n* Refusal to sign the informed consent form",{"count":20,"type":21},[55],"NA","The primary objective of this study is to investigate the effects of a multidisciplinary intervention, including a targeted adapted physical activity program, on lipid oxidation during a walking exercise in women with overweight or obesity, with or without polycystic ovary syndrome. Specifically, the study aims to compare changes in lipid oxidation before and after the intervention between women with polycystic ovary syndrome and those without polycystic ovary syndrome.\n\nThe secondary objectives are to assess the impact of polycystic ovary syndrome on several physiological and metabolic parameters in women with overweight or obesity. These include: (i) resting energy metabolism; (ii) resting blood pressure and heart rate; (iii) energy expenditure, energy cost, and heart rate during a walking exercise; (iv) body composition, glycemic and lipid profiles, and circulating levels of sex hormones and adipokines; (v) movement behaviors; and (vi) physical fitness.\n\nIn addition, the effect of the multidisciplinary intervention, including the adapted physical activity program, will be evaluated on these same outcomes: (i) resting energy metabolism; (ii) resting blood pressure and heart rate; (iii) energy expenditure, energy cost, and heart rate during walking exercise; (iv) body composition, glycemic and lipid profiles, and concentrations of sex hormones and adipokines; (v) movement behaviors; and (vi) physical fitness, in women with overweight or obesity, with or without polycystic ovary syndrome.",[27,58],"Overweight , Obesity",[60,61,62,63],"polycystic ovary syndrome","women","cardiometabolic","Physical activity","NOT_YET_RECRUITING","2026-06-16",{"date":67,"type":36},"2026-06-22",{"date":69,"type":21},"2026-07",{"date":71,"type":21},"2028-12",{"name":73,"class":43},"University Hospital, Clermont-Ferrand",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":18,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":44},"100640120","phase-3-efficacy-of-alpha-lipoic-acid-combined-with-myo-inositol-in-non-diabetic-pcos-patients-100640120","NCT07630779","Efficacy of Alpha Lipoic Acid Combined With Myo-Inositol in Non-Diabetic PCOS Patients","A Randomized Controlled Trial Evaluating the Efficacy of Alpha Lipoic Acid Combined With Myo-Inositol With or Without Metformin in Non-Diabetic Women With Polycystic Ovary Syndrome","ALA-MYO-PCOS","Inclusion Criteria:\n\n* Women aged 21 to 40 years\n* Diagnosed with polycystic ovary syndrome (PCOS) according to Rotterdam criteria\n* Not currently pregnant or lactating\n* No hormonal therapy within the last 3 months\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* \\- History of diabetes mellitus, hypertension, or thyroid disorders\n* History of cardiovascular, renal, or hepatic disease\n* Use of hormonal contraceptives or insulin sensitizers within the last 3 months\n* Known hypersensitivity or allergy to study medications (myo-inositol, alpha-lipoic acid, or metformin)\n* Non-Egyptian ethnicity","21 Years",{"count":84,"type":21},180,[86],"PHASE3","This study evaluates the efficacy of alpha-lipoic acid combined with myo-inositol, with or without metformin, in improving menstrual regularity and ovulation in non-diabetic women with polycystic ovary syndrome (PCOS). The study also assesses metabolic, hormonal, and clinical outcomes.",[27],[90],"PCOS Myo-Inositol Alpha Lipoic Acid Metformin Insulin Resistance Ovulation","2026-06-02",{"date":93,"type":36},"2026-06-05",{"date":95,"type":36},"2026-03-10",{"date":97,"type":21},"2026-12",{"name":99,"class":43},"Beni-Suef University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":44},"100527045","phase-2-efficacy-of-vildagliptin-versus-metformin-in-poly-cystic-ovary-syndrome-100527045","NCT06142656","Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome","Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome: A Randomized Clinical Trial","Inclusion Criteria:\n\n-Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria.\n\nExclusion Criteria:\n\n* Patients with history of diabetes mellitus (Type 1 or 2).\n* Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event within last three months\n* Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4) inhibitors\n* Eating disorders (anorexia, bulimia) or gastrointestinal disorders","50 Years",{"count":109,"type":21},60,[111,86],"PHASE2","Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM",[27],"2025-07-28",{"date":116,"type":36},"2025-07-30",{"date":118,"type":36},"2023-11-25",{"date":120,"type":21},"2026-02-01",{"name":122,"class":43},"October 6 University"]